Multitarget strategy of GATA3 and high-grade serous ovarian carcinoma: Where are we now?

Mohnad Abdalla; Amr Ahmed El-Arabey; Zhongtao Gai

doi:10.1016/j.thromres.2024.02.013

Multitarget strategy of GATA3 and high-grade serous ovarian carcinoma: Where are we now?

Thromb Res. 2024 Apr:236:1-3. doi: 10.1016/j.thromres.2024.02.013. Epub 2024 Feb 16.

Authors

Mohnad Abdalla¹, Amr Ahmed El-Arabey², Zhongtao Gai³

Affiliations

¹ Research Institute of Pediatrics Children's Hospital Affiliated to Shandong University, Jinan Children's Hospital, Jinan, China.
² Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Cairo 11751, Egypt. Electronic address: ph.amrcapa@gmail.com.
³ Research Institute of Pediatrics Children's Hospital Affiliated to Shandong University, Jinan Children's Hospital, Jinan, China. Electronic address: gaizhongtao@sina.com.

PMID: 38368672
DOI: 10.1016/j.thromres.2024.02.013

No abstract available

Keywords: Cancer-associated fibroblasts; High-grade serous ovarian carcinoma; Platelets; Stem cells; Tumor-associated macrophages; Venous thrombosis.

Publication types

Letter

MeSH terms

Female
GATA3 Transcription Factor
Humans
Ovarian Neoplasms* / drug therapy

Substances

GATA3 protein, human
GATA3 Transcription Factor